Seelos Therapeutics, INC

Seelos Therapeutics has filed for Chapter 11 bankruptcy, leading to its stock being moved to the OTC Pink Market and the suspension of its SEC reporting obligations.

Seelos Therapeutics has announced a second postponement of its 2024 Annual Meeting of Stockholders due to an anticipated lack of quorum.

Seelos Therapeutics will be delisted from the Nasdaq due to non-compliance with minimum stockholders' equity requirements and will begin trading on the OTCQB market.

Seelos Therapeutics has been granted a final extension by the Nasdaq Hearings Panel to regain compliance with listing requirements, specifically regarding minimum share price and market value.

Seelos Therapeutics has postponed its 2024 Annual Meeting of Stockholders due to an anticipated lack of quorum, rescheduling it for October 25, 2024.

Seelos Therapeutics has implemented a 1-for-16 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement.

Seelos Therapeutics announces Q2 2024 financial results, highlighting a strategic focus on mental health initiatives and ongoing efforts to address financial challenges.

Seelos Therapeutics, a clinical-stage biopharmaceutical company, announced its financial results for the first quarter of 2024 and provided updates on its clinical programs, highlighting challenges and strategic decisions.

Seelos Therapeutics has filed an amendment to its annual report to include previously omitted information regarding directors, executive compensation, and related matters.

Seelos Therapeutics details its capital structure, outstanding warrants, convertible notes, and anti-takeover provisions in a recent SEC filing.

Michael Joseph Golembiewski, CFO of Seelos Therapeutics, acquired 417 shares of common stock under the company's Employee Stock Purchase Plan on February 29, 2024.

Seelos Therapeutics has further postponed its 2024 Annual Meeting of Stockholders to November 25, 2024, due to an anticipated lack of quorum.

Seelos Therapeutics has postponed its 2024 Annual Meeting of Stockholders from September 27, 2024, to October 25, 2024, due to an anticipated lack of quorum.

Seelos Therapeutics has scheduled its annual stockholders meeting for September 27, 2024, to vote on director elections, auditor ratification, executive compensation, and proposals related to convertible notes and warrant inducements.

Seelos Therapeutics is seeking to raise capital through a public offering of common stock and warrants to fund general corporate purposes and advance its product pipeline.

Seelos Therapeutics has filed a registration statement for the resale of up to 924,414 shares of its common stock, which are issuable upon the exercise of outstanding warrants held by selling stockholders.

Seelos Therapeutics has filed an amendment to its Form S-1 registration statement, primarily concerning the resale of common stock issuable upon the exercise of outstanding warrants.

Seelos Therapeutics is registering the resale of 3,404,256 shares of common stock issuable upon exercise of warrants previously issued to selling stockholders.